MEDICLINIC INTERNATIONAL PLC - Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer

Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer

Mediclinic International PLC
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or the "Company")


23 November 2017

Purchase of shares in Mediclinic by Jurgens Myburgh, Chief Financial Officer

On 21 November 2017, Jurgens Myburgh, Chief Financial Officer, acquired 30,000 shares in the
Company at ZAR 100.70 per share. Accordingly, Mr Myburgh now owns a total of 60,000 shares in
Mediclinic International plc.

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.


NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

  1.    Details of PDMR / person closely associated with them ("PCA")
  a)    Name                     Petrus Jurgens Myburgh

  2.    Reason for the notification
  a)    Position / status        Chief Financial Officer of the Company
  b)    Initial notification /   Initial Notification
        amendment

  3.    Details of the issuer, emission allowance market participant, auction platform, auctioneer or
        auction monitor
  a)    Name                     Mediclinic International plc
  b)    LEI                      2138002S5BSBIZTD5I60

  4.    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
        type of transaction; (iii) each date; and (iv) each place where transactions have been
        conducted

  a)    Description of the       Ordinary Shares
        financial instrument
        Identification Code      GB00B8HX8Z88

  b)    Nature of the            Purchase of shares
        transaction

  c)    Price(s) and             Prices (ZAR)               Volumes
        volume(s)                100.7                      30,000
                        

  d)    Aggregated
        information

        Aggregated volume          30,000
        Price                      ZAR 100.70 per share

  e)    Date of the                21 November 2017; 08:00 UTC
        transaction

  f)    Place of the               Johannesburg Stock Exchange
        transaction



About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South
Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the
quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-
based private healthcare group.

Mediclinic comprises 75 hospitals and 29 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in
total; Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1
700 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 23 clinics with more than 700
inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international private
healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986,
with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai).
The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in
South Africa and the NSX in Namibia.

For further information, please contact:

Link Company Matters Limited
Victoria Dalby / Caroline Emmet
+44 (0)20 7954 9600

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard / Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000


Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 23/11/2017 05:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.